Form 4: Karyopharm Officer Sells Shares for Tax Obligation

Karyopharm Therapeutics' Chief Accounting Officer, Kristin Abate, sold 265 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Summary

• Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc. (KPTI), reported a sale of 265 shares of common stock.
• The transaction occurred on January 21, 2026, at a price of $5.96 per share.
• This sale was not a discretionary trade but was executed pursuant to a durable automatic sale instruction plan (Rule 10b5-1 plan) adopted on May 27, 2021.
• The purpose of the sale was to satisfy withholding tax liability incurred upon the vesting of restricted stock units.
• Following this transaction, Kristin Abate beneficially owns 22,580 shares of Karyopharm Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary sale to cover tax liabilities from restricted stock unit vesting, executed under a pre-arranged Rule 10b5-1 plan. It does not indicate a change in management's confidence or a strategic shift.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• "This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person."

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans for tax withholding purposes, are common across all industries. They typically do not reflect a change in management's discretionary view of the company's prospects but rather a pre-planned, non-discretionary event.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary sale of a small number of shares by an officer to cover tax obligations, not indicative of a change in company fundamentals or management's outlook.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of shares by an officer to cover tax liabilities from restricted stock unit vesting, executed under a pre-arranged Rule 10b5-1 plan. This type of transaction is common and does not provide new information that would warrant a change in investment thesis or a discretionary buy/sell recommendation. Therefore, a 'hold' recommendation is appropriate as there's no new fundamental insight to alter existing positions.

Keywords

Karyopharm Therapeutics, KPTI, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Rule 10b5-1 Plan, Chief Accounting Officer